Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Edap TMS S.A

This article was originally published in The Gray Sheet

Executive Summary

Edap TMS S.A: FDA approval of a premarket approval application supplement for the firm's Prostatron version 2.5 transurethral microwave thermotherapy (TUMT) device for treatment of moderate to severe benign prostatic hyperplasia obstruction is expected "in the coming weeks," Edap's Eric Simon, CEO, stated Oct. 27 at the Oppenheimer conference in New York City. The PMA supplement was filed in April. Edap's Prostatron version 2.0 was approved in May 1996 for treatment of symptomatic BPH ("The Gray Sheet" May 13, 1996, I&W-1). Edap's product pipeline also includes a compact, mobile version of the Prostatron and high-intensity focused ultrasound technology for the minimally-invasive destruction of certain types of tumors ("The Gray Sheet" May 19, I&W-3)...



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts